COLARIS AP ® detects mutations in the APC and MYH genes, which cause adenomatous polyposis colon cancer syndromes, including familial adenomatous polyposis (FAP), attenuated FAP (AFAP) and MYH -associated polyposis (MAP). The most common adenomatous polyposis conditions are thought to account for approximately two percent of all colon cancer.
COLARIS AP ® uses a simple blood or oral rinse sample to determine if patients have an APC or MYH mutation. Knowing the results may help patients and their healthcare providers act before cancer has a chance to develop.
Myriad has developed a Hereditary Cancer Quiz that patients and their healthcare providers can use to help identify potential candidates for genetic testing with COLARIS AP ®.
The results of the COLARIS AP ® test enable patients and their healthcare professionals to develop an individualized medical management plan to significantly reduce the risk of cancer. COLARIS AP ® helps healthcare professionals to:
If a COLARIS AP ® test result confirms the presence of adenomatous polyposis syndromes, the following medical management options may help reduce or even eliminate the risk of cancer.
For more healthcare professional information or to order a COLARIS AP ® test kit, please visit MyriadPro.com.
Myriad Genetics First Quarter 2022 Financial Results Conference Call